Acquired haemophilia A (AHA) is a rare bleeding disorder caused by the development of specific autoantibodies against naturally occurring factor VIII (FVIII). Although about half of cases are idiopathic, AHA may be associated with several non-neoplastic conditions, autoimmune disorders, as well as haematological malignancies, such as chronic lymphocytic leukaemia and lymphoma. The long-term suppression of inhibitors is one of the mainstays of the treatment of AHA. Apart from standard immunosuppressive treatments, rituximab has been proven to be effective in AHA.
The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A / D'Arena, G; Grandone, E; DI MINNO, Matteo; Musto, P; DI MINNO, Giovanni. - In: BLOOD TRANSFUSION. - ISSN 1723-2007. - (2016), pp. 255-261. [10.2450/2015.0090-15]
The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A
DI MINNO, MATTEO;DI MINNO, GIOVANNI
2016
Abstract
Acquired haemophilia A (AHA) is a rare bleeding disorder caused by the development of specific autoantibodies against naturally occurring factor VIII (FVIII). Although about half of cases are idiopathic, AHA may be associated with several non-neoplastic conditions, autoimmune disorders, as well as haematological malignancies, such as chronic lymphocytic leukaemia and lymphoma. The long-term suppression of inhibitors is one of the mainstays of the treatment of AHA. Apart from standard immunosuppressive treatments, rituximab has been proven to be effective in AHA.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
